Using biomarkers to choose depression treatment
Treatments studied
Part of Mental health clinical trials.
This study uses a blood test (biomarker) to help pick the antidepressant that might work best for you. It compares two treatments—standard antidepressants and ketamine—in people with major depression who haven't gotten enough relief from one prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with major depression and currently have at least moderate symptoms.
- You have tried at least one standard depression treatment (like an SSRI or therapy) and it didn't work well enough or you couldn't tolerate it.
- You are either not taking antidepressants now, or you have been on a stable dose for at least a month and plan to stay on that dose.
- You are willing to use effective birth control (if female) and avoid pregnancy during the study.
- You do not have conditions that prevent you from having an MRI or receiving ketamine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a single dose of ketamine affects certain brain and body markers in people with severe depression. It aims to find better ways to predict who will respond to ketamine, which may help personalize depression treatment in the future.
This study looks for genetic and biological markers to help doctors choose the best depression treatment for each person. It aims to make treatment more personalized and effective.
This study is testing whether a new type of brain stimulation called intermittent theta burst stimulation (iTBS) can help people with treatment-resistant depression (depression that hasn't improved with standard medicines). It also looks at certain blood markers to see if they can predict how well someone will respond to this treatment.
This trial tests whether a single dose of ketamine can quickly improve depression by studying brain chemical changes using MRI. It's for people with treatment-resistant depression who haven't used ketamine before.
This early-stage study looks at how parts of brain cells respond to ketamine in people with depression who have not improved with usual antidepressants. It may help researchers find why ketamine works for some people and not others, and who might benefit.
This trial tests whether using brain-related “biomarkers” from your scans to guide rTMS can improve depression that hasn’t responded to at least one antidepressant. It may help by targeting brain circuits linked to depression more precisely.
Hear when a new Depression - Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.